% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Frank:154144,
      author       = {Frank, J. and Lang, M. and Witt, S. H. and Strohmaier, J.
                      and Rujescu, D. and Cichon, S. and Degenhardt, F. and
                      Nöthen, M. M. and Collier, D. A. and Ripke, S. and Naber,
                      D. and Rietschel, M.},
      title        = {{I}dentification of increased genetic risk scores for
                      schizophrenia in treatment-resistant patients},
      journal      = {Molecular psychiatry},
      volume       = {20},
      issn         = {1476-5578},
      address      = {London},
      publisher    = {Macmillan},
      reportid     = {FZJ-2014-03537},
      pages        = {150-151},
      year         = {2015},
      abstract     = {Schizophrenia is a severe neuropsychiatric disorder that
                      affects around $0.5–1\%$ of the population. Research has
                      shown that early intervention increases the likelihood of
                      remission and reduces the severity of symptoms, as well as
                      attenuates the decline in social and overall
                      functioning.1Around $30\%$ of patients fail to respond
                      adequately to the usual antipsychotic medications, and are
                      classified as being treatment resistant. These patients can
                      be treated with the atypical antipsychotic clozapine, the
                      only evidence-based pharmacotherapy for treatment-resistant
                      schizophrenia. However, clozapine is associated with severe
                      adverse events and is thus only prescribed in patients who
                      have failed to respond to trials of two other
                      antipsychotics. This process may take many years. Since an
                      extended duration of untreated psychosis and lack of
                      efficacy for the initial treatment are however associated
                      with a poorer prognosis,6 identification of patients who
                      will eventually require clozapine is an important goal for
                      improving clinical outcome. Research to identify clinical
                      predictors of response prior to treatment initiation has
                      shown that premorbid social functioning (PSF) is among the
                      most reliable measures (for a review see Schennach et al.6).
                      Furthermore, reports of an association between a family
                      history of psychosis and an unfavourable treatment response7
                      suggest the influence of genetic factors. However, few
                      candidate gene studies have been conducted and their results
                      are inconsistent.},
      cin          = {INM-1},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-1-20090406},
      pnm          = {571 - Connectivity and Activity (POF3-571)},
      pid          = {G:(DE-HGF)POF3-571},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000349986700001},
      pubmed       = {pmid:24888364},
      doi          = {10.1038/mp.2014.56},
      url          = {https://juser.fz-juelich.de/record/154144},
}